Physician
Mirafzali, Vahid
Mirafzali, Vahid was paid $6.17M by Medicaid between Jan 2018 and Dec 2024, across 62 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 23% of everything it billed.
33Billing provider infoMIRAFZALI, VAHID
BROWNSVILLE, TX 78526
BROWNSVILLE, TX 78526
33aNPI1851457691assigned 12/28/2006
33bProvider typePediatrics Physician
28Total paid$6.17M
24GClaims349,059
24DCodes billed62
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#65 of 1,136
Median peer was paid$329K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,339 | $27K | |
| 2019 | 1,607 | $34K | |
| 2020 | 10,780 | $187K | |
| 2021 | 71,167 | $1.35M | |
| 2022 | 104,391 | $1.86M | |
| 2023 | 91,118 | $1.58M | |
| 2024incomplete | 68,657 | $1.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 23% | 35,598 | 31,310 | $1.42M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 22% | 64,164 | 51,023 | $1.36M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 7.4% | 5,327 | 5,105 | $455K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.3% | 5,619 | 5,455 | $451K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 7.3% | 31,710 | 26,786 | $448K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 6.3% | 46,011 | 20,730 | $390K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.2% | 4,242 | 4,147 | $323K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4.8% | 28,642 | 11,980 | $293K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.0% | 3,547 | 3,422 | $249K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.5% | 26,327 | 24,129 | $217K |
| 99429 | 1.1% | 2,133 | 2,103 | $70K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,044 | 13,434 | $54K |
50 more codes
| 99381 | <1% | 549 | $41K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 744 | $37K |
| 90461 | <1% | 8,070 | $36K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 465 | $35K |
| 99000 | <1% | 6,239 | $34K | |
| 99051 | <1% | 5,676 | $30K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,740 | $29K |
| 87807 | <1% | 4,469 | $27K | |
| 17110 | <1% | 268 | $23K | |
| 97169 | <1% | 1,195 | $20K | |
| CP002 | <1% | 1,962 | $19K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 472 | $15K |
| 86580 | <1% | 2,265 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,119 | $13K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 445 | $12K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,311 | $10K |
| 0071A | <1% | 231 | $9K | |
| 0072A | <1% | 198 | $8K | |
| 81003 | <1% | 6,247 | $6K | |
| 96160 | <1% | 4,400 | $6K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 398 | $4K |
| 36410 | <1% | 753 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,812 | $2K |
| 84030 | <1% | 375 | $1K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 30 | $441.04 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 76 | $357.75 |
| 73600 | <1% | 13 | $239.94 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 12 | $173.16 |
| 73120 | <1% | 12 | $150.82 | |
| 90686 | <1% | 2,040 | $19.45 | |
| 90671 | <1% | 1,116 | $3.45 | |
| 90651 | <1% | 2,167 | $1.65 | |
| 90620 | <1% | 1,720 | $1.37 | |
| 90715 | <1% | 971 | $0.05 | |
| 90734 | <1% | 2,415 | $0.01 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 1,466 | $0.00 |
| 90680 | 0% | 1,950 | $0.00 | |
| 90723 | 0% | 2,002 | $0.00 | |
| 90696 | 0% | 555 | $0.00 | |
| 90697 | 0% | 183 | $0.00 | |
| 91307 | 0% | 443 | $0.00 | |
| 90716 | 0% | 30 | $0.00 | |
| 90688 | 0% | 19 | $0.00 | |
| 94760 | 0% | 18 | $0.00 | |
| 90648 | 0% | 2,885 | $0.00 | |
| 90710 | 0% | 1,570 | $0.00 | |
| 90633 | 0% | 1,781 | $0.00 | |
| 90670 | 0% | 2,367 | $0.00 | |
| 90700 | 0% | 424 | $0.00 | |
| 90707 | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.